|
|
Vaccine Detail
|
H3.3K27M-specific Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: H3.3K27M-specific Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: H3.3-K27M targeted neoantigen peptide (NCT04749641; NCIT_C132684)
- Immunization Route: subcutaneous injection
- Description: This is a vaccine composed of a peptide derived from histone H3.3 containing the amino acid substitution mutation lysine (Lys) 27-to-methionine (H3.3K27M), with potential immunoactivating and antineoplastic activities. Following the administration of the vaccine, the immune system may exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against H3.3K27M-expressing tumor cells. (NCIT_C132684) A lysine 27-to-methionine (K27M) somatic mutation at histone H3 variant (H3.3) is a feature mutation in diffuse intrinsic pontine gliomas (DIPGs). This vaccine contains an H3.3-K27M targeted neoantigen peptide that can be taken up by antigen-presenting cells (APCs). APCs can present the peptide with the major histocompatibility complex (MHC) molecules on cell surface, thereby activating neoantigen-specific T cells and triggering corresponding cytotoxic T cell immune responses to eliminate H3.3-K27M-expressing DIPG cells. (NCT04749641)
|
| Host Response |
|
|
| References |
NCIT_C132684: H3.3K27M-specific Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C132684]
NCT04749641: Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma (ENACTING) [https://clinicaltrials.gov/study/NCT04749641]
|
|
